Payment overview · 2025
General Payments
$554.49
28 reported records · 6 companies
Healthcare provider profile · identity verified
Joshua Peter Cole, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · PORTSMOUTH, NH · NPI 1497844526
Verified facts
What the public records show
CMS Open Payments records show Joshua Peter Cole, MD received $554.49 in general payments during 2025 across 28 reported records.
Axsome Therapeutics, Inc. accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Auvelity, Invega Sustenna, Lybalvi, Rexulti.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Lybalvi by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Auvelity by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Invega Sustenna by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $217.46 | 39.2% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $114.63 | 20.7% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $79.47 | 14.3% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $64.90 | 11.7% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $58.06 | 10.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.97 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $554.49 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $217.46 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $114.63 | 5 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $79.47 | 4 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $64.90 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $43.60 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $43.18 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 238 | exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
238 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Olanzapine | Olanzapine | 259 | 12 |
| Gabapentin | Gabapentin | 238 | 24 |
| Invega Sustenna | Paliperidone Palmitate | 238 | 16 |
| Clozapine | Clozapine | 177 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 145 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 133 | 16 |
| Olanzapine Odt | Olanzapine | 125 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 125 | 12 |
| Risperidone | Risperidone | 116 | 14 |
| Mirtazapine | Mirtazapine | 113 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 111 | suppressed |
| Lamotrigine | Lamotrigine | 107 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 101 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 100 | suppressed |
| Bupropion Xl | Bupropion Hcl | 98 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 95 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 93 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 92 | suppressed |
| Clonazepam | Clonazepam | 84 | suppressed |
| Clozapine Odt | Clozapine | 84 | suppressed |
| Alprazolam | Alprazolam | 76 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | suppressed |
| Lorazepam | Lorazepam | 76 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 71 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | suppressed |
| Metformin Hcl | Metformin Hcl | 70 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 70 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 60 | suppressed |
| Vraylar | Cariprazine Hcl | 55 | suppressed |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Paliperidone Er | Paliperidone | 49 | suppressed |
| Caplyta | Lumateperone Tosylate | 47 | suppressed |
| Diazepam | Diazepam | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Horizant | Gabapentin Enacarbil | 46 | suppressed |
| Aripiprazole Odt | Aripiprazole | 44 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 44 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 44 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 40 | suppressed |
| Rexulti | Brexpiprazole | 36 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Haloperidol | Haloperidol | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Aristada | Aripiprazole Lauroxil | 29 | suppressed |
| Abilify Maintena | Aripiprazole | 28 | suppressed |
| Armodafinil | Armodafinil | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 26 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 24 | suppressed |
| Jornay Pm | Methylphenidate Hcl | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Lamotrigine Er | Lamotrigine | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Perphenazine | Perphenazine | 21 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 17 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 17 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Lisinopril | Lisinopril | 16 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Risperidone Odt | Risperidone | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Risperidone Er | Risperidone Microspheres | 13 | suppressed |
| Dexmethylphenidate Hcl | Dexmethylphenidate Hcl | 12 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 11 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $554.49 · 28 records | Axsome Therapeutics, Inc. | ABILIFY ASIMTUFII, ARISTADA, Auvelity, COBENFY, INVEGA SUSTENNA, LYBALVI, REXULTI, SPRAVATO | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error